Advantages of MelArray over Oncomine Focus Assay for Mutation Analysis in Melanoma.

Quacoe AE, Freiberger SN, Levesque MP, Dummer R, Ramelyte E

DOI: 10.3390/medicina62030510
Published: 2026 Mar 10
Container: Medicina (Kaunas, Lithuania)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/medicina62030510,
  title = {Advantages of MelArray over Oncomine Focus Assay for Mutation Analysis in Melanoma.},
  author = {Quacoe AE and Freiberger SN and Levesque MP and Dummer R and Ramelyte E},
  year = {2026},
  journal = {Medicina (Kaunas, Lithuania)},
  doi = {10.3390/medicina62030510},
  url = {https://doi.org/10.3390/medicina62030510}
}

RIS

TY  - JOUR
TI  - Advantages of MelArray over Oncomine Focus Assay for Mutation Analysis in Melanoma.
AU  - Quacoe AE
AU  - Freiberger SN
AU  - Levesque MP
AU  - Dummer R
AU  - Ramelyte E
PY  - 2026
JO  - Medicina (Kaunas, Lithuania)
DO  - 10.3390/medicina62030510
UR  - https://doi.org/10.3390/medicina62030510
ER  -

APA

AE, Q., SN, F., MP, L., R, D., & E, R. (2026). Advantages of MelArray over Oncomine Focus Assay for Mutation Analysis in Melanoma.. Medicina (Kaunas, Lithuania). https://doi.org/10.3390/medicina62030510

Source records

pubmed · retrieved 2026-09-25T11:58:07.723Z